Minimally invasive esophagectomy for esophageal cancer: evolution and review.

Surg Laparosc Endosc Percutan Tech

Department of Surgery, School of Medicine, University of Louisville, Louisville, KY 40292, USA.

Published: October 2012

Esophageal cancer remains one of the most deadly cancers with a low overall 5-year survival rate of 17%. Surgical options for esophageal cancer are varied, and debate exists on the best option. The literature was searched for articles discussing minimally invasive esophagectomy (MIE) compared with open esophagectomy (OE), and articles were chosen at the discretion of the authors. Several studies have shown that MIE has a statistically significant rate of decreased blood loss, increased length of operative time, shorter hospital stay, and overall decreased morbidity. Anastomotic leak, stricture rate, and survival benefit have also been demonstrated to be similar between OE and MIE. As is made apparent by the small amount of literature on MIE, further research must be done to determine outcomes. Although it is likely that MIE does offer benefits when compared with open surgery, it has not been shown in any large-scale comparative studies.

Download full-text PDF

Source
http://dx.doi.org/10.1097/SLE.0b013e31826295a4DOI Listing

Publication Analysis

Top Keywords

esophageal cancer
12
minimally invasive
8
invasive esophagectomy
8
compared open
8
mie
5
esophagectomy esophageal
4
cancer evolution
4
evolution review
4
review esophageal
4
cancer remains
4

Similar Publications

Evidence summary on management strategies for gastroesophageal reflux symptoms in patients following esophageal cancer surgery.

Asia Pac J Oncol Nurs

December 2025

Esophageal Oncology Department, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.

Objective: This study aimed to summarize evidence-based strategies for the self-management of gastroesophageal reflux symptoms (GERS) at home among patients who have undergone esophageal cancer surgery, providing practical references for clinical practice.

Methods: A systematic evidence summary was conducted based on the reporting standards of the Fudan University Center for Evidence-based Nursing. Literature was retrieved from international and Chinese databases, including guidelines, expert consensus, systematic reviews, and original studies.

View Article and Find Full Text PDF

Introduction: Individuals with esophageal and gastroesophageal junction (GEJ) cancers are at especially high risk of malnutrition. However, most patients with malnutrition do not receive adequate nutritional support. We conducted a single-arm trial to test the implementation of Support Through Remote Observation and Nutrition Guidance (STRONG), a multilevel digital intervention to improve nutritional outcomes for patients with locally advanced esophageal and gastroesophageal junction cancer.

View Article and Find Full Text PDF

Background: Patients with lung adenocarcinoma (LUAD) receiving drug treatment often have an unpredictive response and there is a lack of effective methods to predict treatment outcome for patients. Dendritic cells (DCs) play a significant role in the tumor microenvironment and the DCs-related gene signature may be used to predict treatment outcome. Here, we screened for DC-related genes to construct a prognostic signature to predict prognosis and response to immunotherapy in LUAD patients.

View Article and Find Full Text PDF

Background: The delivery of cancer services changed significantly during the COVID-19 pandemic. This study aimed to describe changes in presentations, assess the change in recommendations by the MDT during the pandemic, and describe the subsequent long-term impact of these changes on survival rates in patients with EG cancer.

Methods: A retrospective cohort study was designed comparing three patient groups of those referred to EG MDT in the same 6-month period pre-pandemic (PP;2019) during the initial phase of the pandemic (P1;2020) and the year after the initial phase (P2;2021).

View Article and Find Full Text PDF

Digestive cancers: mechanisms, therapeutics and management.

Signal Transduct Target Ther

January 2025

Department of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Cancers of the digestive system are major contributors to global cancer-associated morbidity and mortality, accounting for 35% of annual cases of cancer deaths. The etiologies, molecular features, and therapeutic management of these cancer entities are highly heterogeneous and complex. Over the last decade, genomic and functional studies have provided unprecedented insights into the biology of digestive cancers, identifying genetic drivers of tumor progression and key interaction points of tumor cells with the immune system.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!